Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42

被引:82
作者
Duering, M
Grimm, MOW
Grimm, HS
Schröder, J
Hartmann, T
机构
[1] Ctr mOl Biol Heidelberg, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Sect Gerontopsychiat, Psychiat Clin, D-69115 Heidelberg, Germany
关键词
Alzheimer's disease; beta amyloid-protein; presenilin-1; age of onset; pathogenesis;
D O I
10.1016/j.neurobiolaging.2004.08.002
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
More than 130 known mutations in the presenilin-1 (PS1) gene result in familial Alzheimer's disease (FAD) with a mutation specific age of disease onset. These mutations increase amyloid beta 42 (A beta 42) levels, and this increase has been validated in recent years as one pathogenic factor in FAD. However, further malfunctions of mutant presenilin-1 are discussed as well. In order to assess the weight of A beta 42 regarding the pathogenesis of FAD, we expressed mutant forms of PS1 (30-65 years onset age) in COS-7 cells and analyzed amyloid beta levels by a novel ELISA. We found a strong correlation (r = 0.98; p < 0.00 1) between the A beta 40/42-ratio and mean age of disease onset indicating a substantial extent of A beta 42 contribution to FAD pathology. Our data strongly suggest that A beta 42 is the decisive factor for age of onset in FAD. (c) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:785 / 788
页数:4
相关论文
共 50 条
[31]   Factors affecting the age of onset and rate of progression of Alzheimer's disease [J].
Bowler, JV ;
Munoz, DG ;
Merskey, H ;
Hachinski, V .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 65 (02) :184-190
[32]   Ultrasensitive detection of beta-amyloid 1-42 as a relevant biomarker for Alzheimer's disease in serum [J].
Kim, Dong Hyung ;
Chegal, Won ;
Diware, Mangesh S. ;
Choi, Wook ;
Lee, Nam Hee ;
Cho, Yong Jai ;
Cho, Hyun Mo .
SENSORS AND ACTUATORS B-CHEMICAL, 2023, 396
[33]   Spatial patterns of β-amyloid (Aβ) deposits in familial and sporadic Alzheimer's disease [J].
Armstrong, Richard A. .
FOLIA NEUROPATHOLOGICA, 2011, 49 (03) :153-161
[34]   Amyloid beta 1–42 and tau in the cerebrospinal fluid of renal failure patients for the diagnosis of Alzheimer′s disease [J].
Yat Fung Shea ;
Leung-wing Chu ;
Ming-yee Maggie Mok ;
Man-Fai Lam .
Journal of Nephrology, 2014, 27 :217-220
[35]   Midlife Neuroticism and the age of onset of Alzheimer's disease [J].
Archer, N. ;
Brown, R. G. ;
Reeves, S. ;
Nicholas, H. ;
Boothby, H. ;
Lovestone, S. .
PSYCHOLOGICAL MEDICINE, 2009, 39 (04) :665-673
[36]   Cardiometabolic Modification of Amyloid Beta in Alzheimer's Disease Pathology [J].
Hefner, Marleigh ;
Baliga, Vineet ;
Amphay, Kailinn ;
Ramos, Daniela ;
Hegde, Vijay .
FRONTIERS IN AGING NEUROSCIENCE, 2021, 13
[37]   From beta amyloid to altered proteostasis in Alzheimer's disease [J].
Bruni, Amalia C. ;
Bernardi, Livia ;
Gabelli, Carlo .
AGEING RESEARCH REVIEWS, 2020, 64
[38]   Is amyloid beta-protein glycated in Alzheimer's disease? [J].
Tabaton, M ;
Perry, G ;
Smith, M ;
Vitek, M ;
Angelini, G ;
Dapino, D ;
Garibaldi, S ;
Zaccheo, D ;
Odetti, P .
NEUROREPORT, 1997, 8 (04) :907-909
[39]   Nanomedicine in Alzheimer's disease: Amyloid beta targeting strategy [J].
Tosi, Giovanni ;
Pederzoli, Francesca ;
Belletti, Daniela ;
Vandelli, Maria Angela ;
Forni, Flavio ;
Duskey, Jason Thomas ;
Ruozi, Barbara .
NANONEUROPROTECTION AND NANONEUROTOXICOLOGY, 2019, 245 :57-88
[40]   Oxidized lipoproteins, beta amyloid peptides and alzheimer's disease [J].
Sun, Albert Y. ;
Draczynska-Lusiak, Bozena ;
Sun, Grace Y. .
NEUROTOXICITY RESEARCH, 2001, 3 (02) :167-178